Literature DB >> 34083813

Biomarkers for neurodegenerative diseases.

Oskar Hansson1,2.   

Abstract

Biomarkers for neurodegenerative diseases are needed to improve the diagnostic workup in the clinic but also to facilitate the development and monitoring of effective disease-modifying therapies. Positron emission tomography methods detecting amyloid-β and tau pathology in Alzheimer's disease have been increasingly used to improve the design of clinical trials and observational studies. In recent years, easily accessible and cost-effective blood-based biomarkers detecting the same Alzheimer's disease pathologies have been developed, which might revolutionize the diagnostic workup of Alzheimer's disease globally. Relevant biomarkers for α-synuclein pathology in Parkinson's disease are also emerging, as well as blood-based markers of general neurodegeneration and glial activation. This review presents an overview of the latest advances in the field of biomarkers for neurodegenerative diseases. Future directions are discussed regarding implementation of novel biomarkers in clinical practice and trials.

Entities:  

Year:  2021        PMID： 34083813     DOI： 10.1038/s41591-021-01382-x

Source DB:  PubMed          Journal:  Nat Med        ISSN： 1078-8956            Impact factor:   53.440


  119 in total

Review 1.  The Cellular Phase of Alzheimer's Disease.

Authors:  Bart De Strooper; Eric Karran
Journal:  Cell       Date:  2016-02-11       Impact factor: 41.582

2.  Cerebrospinal fluid levels of β-amyloid 1-42, but not of tau, are fully changed already 5 to 10 years before the onset of Alzheimer dementia.

Authors:  Peder Buchhave; Lennart Minthon; Henrik Zetterberg; Asa K Wallin; Kaj Blennow; Oskar Hansson
Journal:  Arch Gen Psychiatry       Date:  2012-01

3.  Amyloid β deposition, neurodegeneration, and cognitive decline in sporadic Alzheimer's disease: a prospective cohort study.

Authors:  Victor L Villemagne; Samantha Burnham; Pierrick Bourgeat; Belinda Brown; Kathryn A Ellis; Olivier Salvado; Cassandra Szoeke; S Lance Macaulay; Ralph Martins; Paul Maruff; David Ames; Christopher C Rowe; Colin L Masters
Journal:  Lancet Neurol       Date:  2013-03-08       Impact factor: 44.182

Review 4.  Frontotemporal dementia.

Authors:  Jee Bang; Salvatore Spina; Bruce L Miller
Journal:  Lancet       Date:  2015-10-24       Impact factor: 79.321

Review 5.  The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics.

Authors:  John Hardy; Dennis J Selkoe
Journal:  Science       Date:  2002-07-19       Impact factor: 47.728

Review 6.  Lifetime risk of stroke and dementia: current concepts, and estimates from the Framingham Study.

Authors:  Sudha Seshadri; Philip A Wolf
Journal:  Lancet Neurol       Date:  2007-12       Impact factor: 44.182

7.  Autosomal-dominant Alzheimer's disease: a review and proposal for the prevention of Alzheimer's disease.

Authors:  Randall J Bateman; Paul S Aisen; Bart De Strooper; Nick C Fox; Cynthia A Lemere; John M Ringman; Stephen Salloway; Reisa A Sperling; Manfred Windisch; Chengjie Xiong
Journal:  Alzheimers Res Ther       Date:  2011-01-06       Impact factor: 6.982

Review 8.  Protein transmission in neurodegenerative disease.

Authors:  Chao Peng; John Q Trojanowski; Virginia M-Y Lee
Journal:  Nat Rev Neurol       Date:  2020-03-23       Impact factor: 44.711

9.  Spatial patterns of neuroimaging biomarker change in individuals from families with autosomal dominant Alzheimer's disease: a longitudinal study.

Authors:  Brian A Gordon; Tyler M Blazey; Yi Su; Amrita Hari-Raj; Aylin Dincer; Shaney Flores; Jon Christensen; Eric McDade; Guoqiao Wang; Chengjie Xiong; Nigel J Cairns; Jason Hassenstab; Daniel S Marcus; Anne M Fagan; Clifford R Jack; Russ C Hornbeck; Katrina L Paumier; Beau M Ances; Sarah B Berman; Adam M Brickman; David M Cash; Jasmeer P Chhatwal; Stephen Correia; Stefan Förster; Nick C Fox; Neill R Graff-Radford; Christian la Fougère; Johannes Levin; Colin L Masters; Martin N Rossor; Stephen Salloway; Andrew J Saykin; Peter R Schofield; Paul M Thompson; Michael M Weiner; David M Holtzman; Marcus E Raichle; John C Morris; Randall J Bateman; Tammie L S Benzinger
Journal:  Lancet Neurol       Date:  2018-02-01       Impact factor: 44.182

Review 10.  The neuropathological diagnosis of Alzheimer's disease.

Authors:  Michael A DeTure; Dennis W Dickson
Journal:  Mol Neurodegener       Date:  2019-08-02       Impact factor: 14.195
View more
  49 in total

Review 1.  Magnetic Resonance Imaging Studies of Neurodegenerative Disease: From Methods to Translational Research.

Authors:  Peiyu Huang; Minming Zhang
Journal:  Neurosci Bull       Date:  2022-06-30       Impact factor: 5.203

Review 2.  Seed amplification and RT-QuIC assays to investigate protein seed structures and strains.

Authors:  Heidi G Standke; Allison Kraus
Journal:  Cell Tissue Res       Date:  2022-03-08       Impact factor: 5.249

Review 3.  The Key Role of Magnetic Resonance Imaging in the Detection of Neurodegenerative Diseases-Associated Biomarkers: A Review.

Authors:  Ke-Ru Li; An-Guo Wu; Yong Tang; Xiao-Peng He; Chong-Lin Yu; Jian-Ming Wu; Guang-Qiang Hu; Lu Yu
Journal:  Mol Neurobiol       Date:  2022-07-12       Impact factor: 5.682

Review 4.  Promising Blood Biomarkers for Clinical Use in Alzheimer's Disease: A Focused Update.

Authors:  Sun Ah Park; Yu Jung Jang; Min Kyoung Kim; Sun Min Lee; So Young Moon
Journal:  J Clin Neurol       Date:  2022-07       Impact factor: 2.566

Review 5.  The amyloid hypothesis in Alzheimer disease: new insights from new therapeutics.

Authors:  Eric Karran; Bart De Strooper
Journal:  Nat Rev Drug Discov       Date:  2022-02-17       Impact factor: 112.288

6.  Mitochondrial Membrane Potential Influences Amyloid-β Protein Precursor Localization and Amyloid-β Secretion.

Authors:  Heather M Wilkins; Benjamin R Troutwine; Blaise W Menta; Sharon J Manley; Taylor A Strope; Colton R Lysaker; Russell H Swerdlow
Journal:  J Alzheimers Dis       Date:  2022       Impact factor: 4.160

7.  Cellular localization of p-tau217 in brain and its association with p-tau217 plasma levels.

Authors:  Malin Wennström; Shorena Janelidze; K Peter R Nilsson; Geidy E Serrano; Thomas G Beach; Jeffrey L Dage; Oskar Hansson
Journal:  Acta Neuropathol Commun       Date:  2022-01-06       Impact factor: 7.801

Review 8.  The human connectome in Alzheimer disease - relationship to biomarkers and genetics.

Authors:  Meichen Yu; Olaf Sporns; Andrew J Saykin
Journal:  Nat Rev Neurol       Date:  2021-07-20       Impact factor: 44.711

9.  Don't forget about tau: the effects of ApoE4 genotype on Alzheimer's disease cerebrospinal fluid biomarkers in subjects with mild cognitive impairment-data from the Dementia Competence Network.

Authors:  Johannes Kornhuber; Lutz Frölich; Gloria S Benson; Chris Bauer; Lucrezia Hausner; Samuel Couturier; Piotr Lewczuk; Oliver Peters; Michael Hüll; Holger Jahn; Frank Jessen; Johannes Pantel; Stefan J Teipel; Michael Wagner; Johannes Schuchhardt; Jens Wiltfang
Journal:  J Neural Transm (Vienna)       Date:  2022-01-21       Impact factor: 3.850

Review 10.  Recent Developments in Positron Emission Tomography Tracers for Proteinopathies Imaging in Dementia.

Authors:  Ruiqing Ni; Roger M Nitsch
Journal:  Front Aging Neurosci       Date:  2022-01-03       Impact factor: 5.750
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.